I'm not sure about the fair and unbiased case that you refer to.
It seems we have already seen that is not the case in the court system today. And particularly as it relates to Amarin.
The US market is being plundered by the generics who have been allowed to take what isn't theirs in spite of what some posters on this board claim. There are definitive time horizons which drive the need for expediency in plotting a path forward. This should not include a cumbersome litigative path that would be loaded with delays, continuances, etc. And only to find in the end that the bias remains and what has already been decided remains intact.
Emphasis should be on taking advantage of the EU and other markets which have not been compromised by the US court decisions. If none of those can be developed I am afraid we are sorely out of luck here.
Hopefully Sarissa/Denner has a plan in mind that will result in an acceptable end point for all of us.
The Amarin story has dragged on much too long. Let's end it asap rather than extrapolate it.
News 
Market Data 
Discover 
